Target intelligence / Profile preview

Mycobacterial cell envelope glycans and peptidoglycan (mAGP complex) (mAGP complex)

Target
mAGP complex
Molecular classification
Polysaccharide, Peptidoglycan, Glycolipid, Other
01

Overview

The mycobacterial cell envelope is a complex, multi-layered structure characterized by a unique core known as the mycolyl-arabinogalactan-peptidoglycan (mAGP) complex (Brennan, 2003). This structure consists of a peptidoglycan layer covalently linked to a branched arabinogalactan polysaccharide, which is in turn esterified to long-chain mycolic acids. These components provide the bacterium with exceptional structural integrity and create a formidable hydrophobic permeability barrier against many common antibiotics (Abrahams & Besra, 2018). Beyond structural support, glycans like lipoarabinomannan (LAM) play critical roles in modulating the host immune response and facilitating intracellular survival within macrophages (Kaur et al., 2009). Because these pathways are essential for viability and unique to mycobacteria, they serve as the primary targets for first-line anti-tuberculosis drugs such as isoniazid and ethambutol. Disrupting the synthesis or assembly of these glycans and peptidoglycan leads to cell lysis and is a cornerstone of treatment for infections caused by Mycobacterium tuberculosis and other pathogenic mycobacteria. Recent therapeutic strategies also focus on inhibiting the L,D-transpeptidases responsible for peptidoglycan cross-linking, which are distinct from those in other bacteria. The complexity of this target necessitates multi-drug regimens to prevent the emergence of resistance and ensure complete eradication of the pathogen.

Other names
Mycolyl-arabinogalactan-peptidoglycan complexMycobacterial cell wallmAGPLipoarabinomannanArabinogalactan-peptidoglycan complex
02

Mechanism of action

Inhibition of mycolic acid biosynthesis, inhibition of arabinosyltransferase enzymes, and inhibition of peptidoglycan cross-linking (Abrahams & Besra, 2018).

03

Biological functions

Immune responseOther
04

Disease associations

Infection
05

Safety considerations

Drug resistanceHepatotoxicityTherapeutic challenge of drug penetration
06

Interacting drugs

Isoniazid

6 more in the full profile.

07

Biomarkers

Lipoarabinomannan (LAM)

Beyond the preview

Go deeper on Mycobacterial cell envelope glycans and peptidoglycan (mAGP complex) (mAGP complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mycobacterial cell envelope glycans and peptidoglycan (mAGP complex) (mAGP complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call